# Sacituzumab govitEcan in THYroid Cancers

> **NCT06235216** · PHASE2 · RECRUITING · sponsor: **Grupo Espanol de Tumores Neuroendocrinos** · enrollment: 42 (estimated)

## Conditions studied

- Differentiated Thyroid Cancer
- Anaplastic Thyroid Cancer

## Interventions

- **DRUG:** Sacituzumab govitecan

## Key facts

- **NCT ID:** NCT06235216
- **Lead sponsor:** Grupo Espanol de Tumores Neuroendocrinos
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-13
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2024-11-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06235216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06235216, "Sacituzumab govitEcan in THYroid Cancers". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06235216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*